Pure Global
NCT06095479

Ultrasound Liver Fat Quantification on Pediatric Patients

Philips (China) Investment CO., LTD·ClinicalTrials.gov·device·Device trialRecruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Non-Alcoholic Fatty Liver Disease
Drug/Device/Intervention
2D ultrasound scan and MRI examination
Study type
Interventional
Intervention type
device
Sponsor & location
Primary sponsor
Philips (China) Investment CO., LTD
Location
Shanghai, China
Timeline & enrollment
Phase
N/A
Start date
Jul 06, 2021
End date
Jun 30, 2024
Enrollment
90 participants
Primary outcome

Rate of HRIQ, AttenQ and ElastQ, and the liver fat content percentage measured by MRI

Summary

This prospective study aims to recruit pediatric patients with confirmed or suspected
 non-alcoholic fatty liver disease (NAFLD) / non-alcoholic steatosis hepatitis (NASH) and who
 are eligible for standard ultrasound and MRI examinations. All subjects will undergo a 2D
 ultrasound scan and MRI examination. Approximately 108 subjects will be enrolled, targeting
 at 90 completing the study.

ICD-10 classifications
Alcoholic fatty liverAlcoholic liver disease, unspecifiedAlcoholic liver diseaseLiver disease, unspecifiedAlcoholic cirrhosis of liver
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06095479
Type
Device Trial
About this record

Access comprehensive clinical trial information for NCT06095479 through Pure Global AI's free database. This phase not specified trial is sponsored by Philips (China) Investment CO., LTD and is currently Recruiting. The study focuses on Non-Alcoholic Fatty Liver Disease. Target enrollment is 90 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.